Cellectis S.A. is a Paris-based clinical-stage gene-editing biotechnology company that has spent the better part of two decades building an allogeneic, or off-the-shelf, CAR-T platform rooted in its proprietary TALEN nuclease technology. Three wholly owned product candidates are advancing through hematologic and solid tumor trials and a fourth program is in preclinical development. The corporate identity is highly concentrated for a company of this size: AstraZeneca Holdings alone may exercise roughly 40% of the voting power through a combination of ordinary shares and convertible preferred stock. The November 2023 joint research and collaboration agreement with AstraZeneca Ireland now drives the great majority of the topline. The platform is differentiated not by revenue scale but by the breadth of partner leverage. Allogene is running pivotal work on a CD19 program that traces back to a Cellectis license, and Servier continues to be a contractual counterparty even after a December 2025 arbitration award reshaped the long-standing UCART19 relationship.
The recent disclosure calendar centers on a September 2026 foreign private issuer submission filed shortly before this report, which furnishes an updated press release as an exhibit and which provides the regulatory record with one of the freshest public-facing updates on the company. The most recent annual report covers the year ended December 31, 2025. The annual filing was submitted in March. The annual report lays out a balance sheet built around $61.5M of cash and equivalents plus $144.8M of fixed-term deposits classified as current financial assets. This balance sits against an accumulated deficit that has grown to roughly $1B over a multi-decade development arc. The French incorporation, the dual listing on Euronext Growth in Paris and on Nasdaq in New York, the two in-house manufacturing facilities in Paris and Raleigh, and the dependence on a small group of large shareholders together define the structural perimeter of the equity story. The operating picture remains one of a platform company that is still pre-commercial but no longer pre-revenue, with a partnership-anchored income statement and a clinical pipeline that has produced genuinely competitive response data in the lead B-cell indication.
The investment lens for a reader evaluating this equity at the recent trading level near $3.25 should focus on three variables: the rate at which the lead asset converts from Phase 1 data into registrational positioning, the durability of the AstraZeneca research revenue stream as that collaboration matures toward candidate selection milestones, and the dilution profile that any future capital raise would impose on the existing capital structure. None of these variables resolves cleanly in the next two reporting periods, and that is the principal reason the equity trades closer to its recent 52-week low than to its high. The base-case scenario over the medium term is a continued narrowing of operating losses as research revenue scales, modest cash burn that preserves the disclosed runway into the second half of 2027, and incremental clinical readouts from both the wholly owned programs and the Allogene-partnered CD19 candidate. The principal upside scenario is a label-enabling pivotal readout from the BALLI-01 study in r/r B-ALL. The principal downside scenario is a contract dispute that compresses milestone economics on a partner program, or a financing event that meaningfully impairs per-share value.